# Novel Rapid-Acting Drug Proves Effective in Severe PTSD

- URL: https://theranews.net/blog/2026-02-19-novel-rapid-acting-drug-proves-effective-in-severe-ptsd-96fde2/
- Published: 2026-02-19
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: medpagetoday
- Original report: https://www.medpagetoday.com/psychiatry/anxietystress/119935
- Topics: stress
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> (MedPage Today) -- The investigational neuroplastogen TSND-201 showed significant efficacy in patients with severe post-traumatic stress disorder (PTSD), according to results from a phase II randomized trial.Among 65 patients, treatment with...

---
The investigational neuroplastogen TSND-201 showed significant efficacy in patients with severe post-traumatic stress disorder in a Phase II randomized trial. Among 65 patients, treatment with TSND-201 resulted in a statistically significant and clinically meaningful improvement in Clinician-Administered PTSD Scales for DSM-5 total score from baseline to day 64 compared with placebo, with least-squares mean changes of -23.28 and -13.64, respectively (p=0.01).

A statistically significant improvement with TSND-201 was seen as early as day 10 (p=0.01). The treatment also led to significant improvements in secondary endpoints compared with placebo, including changes in PTSD Checklist for DSM-5, Sheehan Disability Scale, and Montgomery-Åsberg Depression Rating Scale scores, suggesting the drug is effective across multiple domains affected by PTSD, including symptoms, functioning, and depression.

TSND-201, also called methylone, is a highly selective, rapid-acting neuroplastogen that releases serotonin, norepinephrine, and dopamine. Despite a short half-life of about 6 hours, weekly dosing in this study resulted in clinical effects lasting up to 6 weeks after the final dose. This durability may be due to its activity as a rapid-acting neuroplastogen, which promotes synaptic plasticity, neurite outgrowth, and neurotrophin expression—processes disrupted by PTSD.

The drug was generally safe and well tolerated. Treatment-emergent adverse events included headache, decreased appetite, nausea, dizziness, increased blood pressure, dry mouth, and insomnia, which were typically transient, occurring on the day of dosing and resolving within a day. The trial was carried out over 10 weeks at 16 sites in the U.S., the U.K., and Ireland. Patients were ages 18 to 65 with PTSD meeting DSM-5 criteria. The FDA granted the drug a breakthrough therapy designation in July 2025, and the company is actively preparing to start its Phase III clinical program.

---

*This article is an AI-assisted summary. All facts and figures are drawn from the original report: [https://www.medpagetoday.com/psychiatry/anxietystress/119935](https://www.medpagetoday.com/psychiatry/anxietystress/119935)*